Edgar Snyder & Associates®
A Law Firm Representing Injured People
Call Us Toll Free 24/7
Published on Dec 04, 2006 by Edgar Snyder

Pfizer’s New Drug Letdown


Pfizer officially announced that it is halting development of what was to be one of their most promising drugs, torcetrapib. The drug was the first in a new class of drugs known as CETP inhibitors, which would have helped increase the amount of “good” cholesterol, or HDL, reducing heart disease.

The decision to pull the drug from development came after reports of 82 deaths of patients taking torcetrapib along with Lipitor during a clinical trial. In addition to the deaths, patients taking the drug experienced an increase in angina, congestive heart failure and procedures to clear clogged arteries.

Pfizer plans on determining if torcetrapib’s problems were caused by a rise in blood pressure that increased the patients’ risk of heart attack and stroke, or if the rising levels of HDL caused the more harm than good. The results of the study will determine if the whole class of drugs won’t work, or if they need to eliminate the blood pressure factor.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio, and West Virginia and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.

Source: “Demise of a Blockbuster Drug Complicates Pfizer’s Revamp.” By Scott Hensley and Ron Winslow. The Wall Street Journal. December 4, 2006.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
Briefly describe your injuries

Recent News

Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Sep 16, 2016
New CDC Tool Will Help Keep Traveling Workers Safe
Sep 14, 2016
PA Residents: You're This Much More Likely to Hit a Deer